CM
EWTX icon

Crestline Management’s Edgewise Therapeutics EWTX Stock Holding History

Crestline Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,268
Closed -$354K – 218
2024
Q4 		$354K Sell
13,268
-13,713
-51% -$437K 0.01% 596
2024
Q3 		$720K Buy
+26,981
New +$537K 0.04% 318

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Crestline Management's EWTX Position: Q1 2025 in Review

Crestline Management sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 13,268 shares — an estimated $354K sold.

Crestline Management first reported a position in EWTX in Q3 2024 and held it in 2 quarters. The position peaked at $720K in Q3 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Crestline Management reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 13,268 Edgewise Therapeutics shares in Q1 2025, an estimated $354K.
  • Crestline Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 2 quarters.
  • Crestline Management's Edgewise Therapeutics position peaked at $720K in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.